180975-66-0

Basic information

• Product Name: tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate
• Synonyms: tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate;1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester, (2R,6S)-;(2R,6S)-tert-Butyl 2,6-diMethylpiperazine-1-carboxylate;1-Boc-(2S,6R)-2,6-diMethylpiperazine;cis-1-Boc-2,6-diMethylpiperazine;cis-2,6-Dimethyl-1-piperazinecarboxylic acid 1,1-dimethylethyl ester;(2R,6S)-rel-tert-Butyl 2,6-dimethylpiperazine-1-carboxylate;tert-butyl (2S,6R)-2,6-dimethylpiperazine-1-carboxylate
• CAS NO: 180975-66-0
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.31
• Mol File: 180975-66-0.mol

Chemical Properties

• Boiling Point: 279.7°C at 760 mmHg
• Flash Point: 123°C
• Appearance: /
• Density: 0.97g/cm³
• Vapor Pressure: 0.00394mmHg at 25°C
• Refractive Index: 1.452
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.53±0.60(Predicted)
• CAS DataBase Reference: tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate(180975-66-0)
• EPA Substance Registry System: tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate(180975-66-0)

Safety Data

• Hazardous Substances Data: 180975-66-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to form important chemical bonds in drug molecules. The presence of the tert-butyl group provides additional stability and protection during the synthesis process, enhancing the compound's utility in creating potential therapeutic agents.
Used in Drug Synthesis:
In the field of drug synthesis, tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate is utilized as a building block for creating complex drug molecules. Its versatile chemical properties allow for a wide range of reactions, facilitating the development of new pharmaceuticals with improved efficacy and safety profiles.
Used in Medicinal Chemistry Research:
Tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate is also employed in medicinal chemistry research for the exploration of novel drug candidates. Its unique stereochemistry and functional groups make it an attractive starting point for the design and optimization of new therapeutic agents targeting various diseases and conditions.
Overall, tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-carboxylate is an essential component in the development of innovative pharmaceuticals, playing a crucial role in the synthesis and research of new drugs with potential therapeutic applications.

InChI:InChI=1/C11H22N2O2/c1-8-6-12-7-9(2)13(8)10(14)15-11(3,4)5/h8-9,12H,6-7H2,1-5H3/t8-,9+

Upstream product

• 623585-97-7 benzyl (3S,5R)-3,5-dimethylpiperazine-1-carboxylate 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 2080367-38-8 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate 
• 1207455-37-5 benzyl 4-(t-butoxycarbonyl)-3,5-dimethylpiperazine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 108-49-6 3,5-dimethylpiperazine 

Relevant articles and documents

JAK1 SELECTIVE INHIBITORS

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.